Clinical trial · Observational
Association of Tumour Grade and Sex Steroid Receptor as a Prognostic Index in Breast Cancer
NCT04707287CI-TRIAL-00049425unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Null hypothesis: Histological grade of tumour bears no relation with the status of sex hormone receptors. Alternate hypothesis: Both the histological grade of tumour and expression of sex steroid receptors are directly related to each other The investigators aim to; 1. see the relationship of sex steroid receptors with the histological grade of breast cancer. 2. evaluate the efficacy of steroid receptors as a prognostic factor
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Breast Cancer Patients
- description
- All the patients irrespective of age, ethnicity and stage of disease will be including once the disease is confirmed after triple assessment
- interventionNames
- Other: No Intervention
Primary outcomes (2)
- measure
- Histopathology of tumour
- timeFrame
- 6 months
- description
- The incidence of grade and type of breast cancer at the time of study will be recorded and analysed
- measure
- Steroid receptor status
- timeFrame
- 6 months
- description
- The concentrations of estrogen and progesterone receptor will be calculated and analysed.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * All patients diagnosed with breast cancer irrespective of age, gender and clinical stage Exclusion Criteria: * Any patient who lost to follow up
References
Publications (5)
- BACKGROUNDGadducci A, Biglia N, Sismondi P, Genazzani AR. Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol. 2005 Jun;20(6):343-60. doi: 10.1080/09513590500128492. PMID 16019385
- BACKGROUNDFolkerd E, Dowsett M. Sex hormones and breast cancer risk and prognosis. Breast. 2013 Aug;22 Suppl 2:S38-43. doi: 10.1016/j.breast.2013.07.007. PMID 24074790
- BACKGROUNDGambardella A, Esposito D, Accardo G, Taddeo M, Letizia A, Tagliafierro R, Esposito K, Pasquali D. Sexual function and sex hormones in breast cancer patients. Endocrine. 2018 Jun;60(3):510-515. doi: 10.1007/s12020-017-1470-7. Epub 2017 Nov 14. PMID 29138989
- BACKGROUNDStute P, Wildt L, Neulen J. The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric. 2018 Apr;21(2):111-122. doi: 10.1080/13697137.2017.1421925. Epub 2018 Jan 31. PMID 29384406
- BACKGROUNDClendenen TV, Ge W, Koenig KL, Afanasyeva Y, Agnoli C, Brinton LA, Darvishian F, Dorgan JF, Eliassen AH, Falk RT, Hallmans G, Hankinson SE, Hoffman-Bolton J, Key TJ, Krogh V, Nichols HB, Sandler DP, Schoemaker MJ, Sluss PM, Sund M, Swerdlow AJ, Visvanathan K, Zeleniuch-Jacquotte A, Liu M. Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model. Breast Cancer Res. 2019 Mar 19;21(1):42. doi: 10.1186/s13058-019-1126-z. PMID 30890167